<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1701244755
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PANREST 40 mg Enteric Coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PANTOPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        39.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX INC. (SIGNET SITE)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>a- How PANREST works</u></strong></p><p>PANREST is used to treat and help heal duodenal and gastric ulcers. Depending on the position of the ulcer it is called a gastric or duodenal ulcer. A gastric ulcer occurs in the stomach. A duodenal ulcer occurs in the duodenum which is the tube leading out of the stomach. These can be caused in part by too much acid being made in the stomach.</p><p>&nbsp;</p><p>Most people who have a peptic ulcer also have bacteria called Helicobacter pylori in their stomach. When PANREST is taken with antibiotics the combination therapy will kill the Helicobacter pylori and let your ulcer heal. PANREST may also be used to prevent ulcers associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs). These are medicines used to relieve pain, swelling and other symptoms of inflammation, including arthritis (inflammation of the joints).</p><p>&nbsp;</p><p>PANREST is also used to treat reflux esophagitis or reflux disease. This can be caused by &quot;washing back&quot; (reflux) of food and acid from the stomach into the food pipe, also known as the esophagus. Reflux can cause a burning sensation in the chest rising up to the throat, also known as heartburn. PANREST is also used to prevent reflux esophagitis from coming back.</p><p>&nbsp;</p><p>PANREST is used to treat a rare condition called Zollinger&shy; EIIison syndrome, where the Stomach produces very large amounts of acid, much more than in ulcers and reflux disease.</p><p>Your doctor may have prescribed it for another reason. Ask your doctor if you have any questions about why this medicine has been prescribed for you. This medicine is available only with a doctor&#39;s prescription. There is no evidence that this medicine is addictive.</p><p>&nbsp;</p><p><strong><u>b- Use in children</u></strong></p><p>There is not enough information to recommend the use of this medicine in children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>a- Do not take PANREST</u></strong></p><ul><li>if you are lactose-intolerant. The tablets contain lactose.</li><li>if you have had an allergic reaction to PANREST or any of the ingredients listed at the end of this leaflet. Some of the symptoms of an allergic reaction may include: shortness of breath, wheezing or difficulty breathing; swelling of the face, lips., tongue, throat or other parts of the body; muscle pain or tenderness or joint pain; or rash, itching or hives on the skin.</li><li>if you have severe liver disease or cirrhosis</li><li>in combination with antibiotics or any other medicine if:<ul><li>you are allergic to any of the antibiotics or medicines your doctor may prescribe with PANREST.</li><li>you have moderate to severe liver or kidney disease.</li></ul></li><li>in combination with atazanavir (an anti-viral medication).</li><li>after the expiry date (EXP) printed on the pack. If you take this medicine after the expiry date has passed, it may not work as well.</li><li>if the packaging is torn, shows signs of tampering or if it does not look quite right. If it has expired or is damaged, return it to your pharmacist for disposal.</li><li>if you are not sure whether you should start taking this medicine, talk to your doctor.</li></ul><p>&nbsp;</p><p><strong><u>b- Warnings and precautions</u></strong></p><p>Recent literature reports revealed an increased number of cases diagnosed with clostridium difficile-associated diarrhea (CDAD). In certain number of studies, both conditions were found to be significantly associated with the use of Proton Pump Inhibitors (PPIs) in hospitalized or non-hospitalized patients. However, some studies did not find link between the CDAD with PPIs administration although the influencing factors are controlled.</p><p>Observational studies found association between use of PPIs and development of CDAD. All studies discussed the rate and risk of CDAD among PPIs users. It was clearly stated in some studies that CDAD is more likely to be associated with PPIs consumption; however, some studies indicated that the risk measurements do not yield a significant association between CDAD and PPIs. The duration of therapy with PPIs found to be unrelated to CDAD episodes.</p><p><strong>Seek immediate care if you use PPIs and develop diarrhea that does not improve. This may be a sign of CDAD. Do not stop taking your prescription PPI drug without talking to your healthcare professional.</strong></p><p>&nbsp;</p><p><strong><u>c- Pregnancy and breast-feeding</u></strong></p><p>Your doctor will discuss the risks and benefits of taking PANREST during pregnancy or while breast-feeding.</p><p>&nbsp;</p><p><strong><u>d- Take special care</u></strong></p><p><strong>Before you start taking this medicine, tell your doctor if you:</strong></p><ul><li>have allergies to PANREST, any other ingredients listed at the end of this leaflet and any other substances, such as foods, preservatives or dyes.</li><li>You have or have had any medical conditions.</li><li>Do not give this medicine to anyone else, even if their symptoms seem similar to yours. Do not take your medicine to treat any other complaints unless your doctor or pharmacist tells you to.</li></ul><p>&nbsp;</p><p><strong><u>e- Driving and using machines</u></strong></p><p>Be careful while driving or operating machinery until you know how PANREST affects you.</p><p>&nbsp;</p><p><strong><u>f- Interactions with this medication</u></strong></p><p>Tell your doctor or pharmacist if you are taking any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food shop.</p><p>Some medicines may be affected by PANREST, or may affect how well it works. These may include medicines used to prevent blood clots (anticoagulants) and medicines whose activity depend on the acidity of the stomach e.g. ketoconazole.</p><p>Your doctor and pharmacist can tell you if you are taking any of these medicines. They may also have more information on medicines to be careful with or avoid while taking PANREST.</p><p>Other interactions not listed above may also occur.</p><p>Some self-help measures suggested below may help your condition. Talk to your doctor or pharmacist about these measures and for more information.</p><ul><li>Alcohol - your doctor may advise you to limit your alcohol intake.</li><li>Aspirin and many other medicines used to treat arthritis, period pain, headaches - these medicines may irritate the stomach and may make your condition worse. Your doctor or pharmacist may suggest other medicines you can take.</li><li>Caffeine- your doctor may advise you to limit the number of drinks which contain caffeine, such as coffee, tea, cocoa and cola drinks, because they contain ingredients that may irritate your stomach.</li><li>Eating habits- eat smaller, more frequent meals. Eat slowly and chew your food carefully. Try not to rush at meal times.</li><li>Smoking - your doctor may advise you to stop smoking or at least cut down.</li><li>Weight - your doctor may suggest losing some weight to help your condition.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all directions given to you by your doctor or pharmacist carefully. They may be different to the information in this leaflet. If you do not understand any written instructions, ask your doctor or pharmacist for help.</p><p>&nbsp;</p><p><strong><u>a- How much PANREST to take</u></strong></p><p>The usual dose is one tablet per day. However, if your doctor also prescribes antibiotics in combination with PANREST for the treatment of duodenal ulcers, the dose of PANREST is two 40 mg tablets per day. The first tablet should be taken in the morning and the second tablet should be taken before the evening meal for 7 days.</p><p>Your doctor will prescribe the dose that is right for you.</p><p>The dose and frequency of PANREST that your doctor prescribes for you depends on your medical condition. Your doctor may change the dose as your condition changes.</p><p>&nbsp;</p><p><strong><u>b- How and When to take PANREST</u></strong></p><p>Swallow your tablets whole with a little water with or without food. <strong>Do not crush or chew the tablets. PANREST tablets have a special coating to protect them from the acidic contents of your stomach. For</strong> <strong>PANREST to work effectively, this coating must not be broken.</strong></p><p>If you are taking other medicines, like antibiotics, in combination with PANREST therapy, follow the instructions for the use of each medicine carefully.</p><p>Take it at about the same time each day. Taking your medicine at the same time each day will have the best effect. It will also help you remember when to take it. Continue taking your medicine for as long as your doctor tells you. Make sure you have enough to last over weekends and holidays.</p><p>&nbsp;</p><p><strong><u>c- If you take more PANREST than should</u></strong></p><p><strong>Immediately telephone your doctor or the Poisons Information Centre for advice, or go to the Accident and Emergency Department at the nearest hospital, if you think that you or anyone else may have taken too much PANREST.</strong></p><p><strong>Do this even if there are no signs of discomfort or poisoning. </strong>You may need urgent medical attention.</p><p>&nbsp;</p><p><strong><u>d- If you forget to take PANREST</u></strong></p><p>If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to. Otherwise, take it as soon as you remember, and then go back to taking your medicine as you would normally. <strong>Do not take a double dose to make up for the dose that you missed. </strong>This may increase the chance of you getting an unwanted side effect. If you have trouble remembering to take your medicine, ask your pharmacist for some hints.</p><p>Do not stop taking your medicine, or change the dosage, without checking with your doctor.</p><p>&nbsp;</p><p><strong><u>e- While you are taking PANREST</u></strong></p><p>Use PANREST exactly as your doctor has prescribed. Tell your doctor immediately if you become pregnant while you are taking PANREST. Tell all doctors, dentists and pharmacists who are treating you that you are taking PANREST. If you take PANREST for a long period of time, e.g. over 1 year, you will need to see your doctor regularly so that he/she can monitor your condition. Tell your doctor if you do not feel better while taking PANREST. Your doctor may recommend further examination.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking PANREST, even if you do not think the problems are connected with the medicine or they are not listed in this leaflet.</strong></p><p>Like other medicines, PANREST can cause some side effects. If they occur, most are likely to be minor and temporary. However, some may be serious and need medical attention. Your doctor has weighed the risks of using this medicine against the benefits they expect it will have for you. Ask your doctor or pharmacist to answer any questions you may have.</p><p>&nbsp;</p><p><strong><u>Hypomagnesaemia:</u></strong></p><p>Reported rarely usually with prolonged PPI use of at least 3 months (in most cases after one year of therapy) may be symptomatic or asymptomatic; sever cases may cause tetany seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentration prior to beginning long-term therapy especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesaemia; and periodically therefore. Hypomagnesaemia may be corrected by magnesium supplementation, although discontinuation of PANREST may be necessary; magnesium levels typically return to normal within one week of stopping.&nbsp;</p><p>Following is a list of possible side effects. Do not be alarmed by this list. You may not experience any of them.</p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist if you notice any of the following and they worry you:</strong></p><ul><li>Headache</li><li>Dizziness</li><li>Diarrhea</li><li>Nausea or vomiting</li><li>Stomach pain</li><li>Excessive gas in the stomach or bowel</li><li>Indigestion</li><li>Constipation</li><li>Dry mouth</li><li>Metallic taste</li><li>Weakness or tiredness</li><li>Increased sweating</li><li>blurred vision</li><li>Skin problems such as Itchiness and rash</li></ul><p>These are the more common side effects of PANREST. Some of these side effects may be due to the combination of other medicines you are taking with PANREST.</p><p>&nbsp;</p><p><strong>Tell your doctor as soon as possible if you notice any of the following:</strong></p><ul><li>Nausea, vomiting, loss of appetite, feeling generally unwell, fever, itching, yellowing of the skin and eyes, and dark colored urine.</li><li>Skin problems such as itchiness and rash, or Swelling, blistering or peeling of the skin.</li><li>Swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing.</li><li>Frequent infections such as Fever, severe chills, sore Throat or mouth ulcers</li><li>Chest pain</li><li>Shortness of breath</li><li>High blood pressure</li><li>Swelling of the legs</li><li>Bleeding or bruising more easily than normal</li><li>Depression, confusion or anxiety</li></ul><p>These may be serious side effects and you may need urgent medical attention. Serious side effects are rare.</p><p>Other side effects not listed above may occur in some people. Tell your doctor if you notice anything that is making you feel unwell when you are taking, or soon after you have finished taking PANREST.</p><p><strong>Ask your doctor or pharmacist if you do not understand some of the information in this list.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep it where children cannot reach it.</li><li>A locked cupboard at least one and a half meters above the ground is a good place to store medicines.</li><li>Keep your medicine in its original packaging until it is time to take them.</li><li>If you take the tablets out of their original packaging they may not keep well.</li><li>Keep your medicine in a cool dry place where the temperature will stay below 30&deg;C.</li><li>Do not store your medicine, or any other medicine, in the bathroom or near a sink. Do not leave it on a window sill or in the car.</li><li>Heat and dampness can destroy some medicines.</li><li>Disposal: If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, ask your pharmacist what to do with any medicine that is left over.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is Pantoprazole sodium</li><li>The other ingredients are lactose, mannitol, crospovidone, microcrystalline cellulose, magnesium stearate, hypromellose, polyethylene glycol 8000, anhydrous sodium carbonate, methacrylic acid Copolymer type C, triethyl citrate, talc titanium dioxide, iron oxide yellow.</li></ul><p>This medicine is gluten-free, sucrose-free, tartrazine-free and other azo dyes-free.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The tablets are available as 20 mg and 40 mg strengths. The tablets have an acid-resistant coating called an enteric coating.

20 mg tablets
The 20 mg tablets are yellow, oval, biconvex, enteric-coated tablets engraved "APO" on one side, "P20" on the other side

Available in blister packs of 30 tablets and bottles of 30, 100 and 500 tablets.

40 mg tablets
The 40 mg tablets are yellow, oval, biconvex, enteric-coated tablets engraved "APO" on one side, "P40" on the other side

Available in blister packs of 30 tablets and bottles of 30, 100 and 500 tablets.

* Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong><u>أ- كيف يعمل </u></strong><strong><u>بانريست</u></strong></p><p dir="RTL">يستعمل بانريست لمعالجة قرحات المعدة و الإثنى عشر و المساعدة على التئامها. و تسمى القرحات بحسب موضعها فهي اما قرحة المعدة أو قرحة الإثنى عشر. قرحة المعدة تحدث في المعدة و قرحة الإثنى عشر تحدث في الإثنى عشر، و هو الأنبوب الخارج من المعدة. و من أسباب حدوث هذه القرحات زيادة كميات الأحماض التي تنتجها المعدة.</p><p dir="RTL">معظم الأشخاص المصابين بتلك القرحات تكون لديهم إصابة في المعدة بنوع من البكتيريا تسمى &quot; هيليكوباكتر بايلوري&quot;. و عندما يؤخذ بانريست جنبا إلى جنب مع مضادات حيوية مناسبة، فإن هذا العلاج المشترك يقتل بكتيريا هيليكوباكتر بايلوري و يساعد على التئام القرحة . و يستخدم بانريست أيضا للوقاية من القرحات المرتبطة باستخدام مضادات الإلتهاب غير السترويدية (ان اس أي آي دي) و هي أدوية تستخدم لتسكين الألم و التورم و غيرها من أعراض الإلتهابات بما في ذلك التهابات المفاصل.</p><p dir="RTL">ويستخدم بانريست أيضا لعلاج مرض الإرتداد المريئي و الذي يحدث بسبب إرتداد (رجوع) الطعام و الشراب و معها الأحماض من المعدة إلى المرئ (الأنبوب الواصل من الفم للمعدة). و هذا الإرتداد يسبب شعورا بالحرقان في الصدر يمتد ليشمل الحلق، و يستخدم بانريست أيضا لمنع عودة الإرتداد.</p><p dir="RTL">كما يستخدم بانريست لعلاج حالة نادرة تسمى &quot;متلازمة زولنجر اليسون&quot; و الذي تفرز فيها المعدة كميات كبيرة من الحامض تزيد عن تلك التي تفرزها في حالات القروح و الإرتداد.</p><p dir="RTL">و قد يكون طبيبك قد وصف لك هذا العلاج لأسباب أخرى. يمكنك أن تسأل الطبيب عن سبب قيامه بوصف هذا الدواء لك. و إن هذا الدواء لا يمكن الحصول عليه ألا بوصفة من الطبيب، و لا توجد أي أدلة على أن هذا الدواء يسبب الإدمان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ب- الإستخدام للأطفال</u></strong></p><p dir="RTL">لا تتوفر معلومات تكفي لكي يتم و صف هذا الدواء للأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><u>أ- متى يجب عدم استخدام بانريست</u></strong></p><ul dir="rtl"><li>إذا كنت لا تستطيع تحمل لاكتوز. لأن هذه الاقراص تحتوي على لاكتوز.</li><li>لا تتناول هذا الدواء إذا كنت تعاني من حساسية للبانريست أو أي من مكوناته المذكورة في نهاية هذه النشرة. و تشمل أعراض ردة فعل الحساسية ما يلي: ضيق في التنفس، أزيز تنفسي أو صعوبة في التنفس، تورم في الوجه أو الشفتين أو اللسان أو الحلق أو غيرها من أعضاء الجسم، و تشمل أيضا أوجاع بالعضلات، ألم بالمفاصل، طفح جلدي، حكة أو بثور على الجلد.</li><li>لا تستعمل بانريست إذا كنت تعاني مرض شديد أو تليف بالكبد.</li><li>لا تستعمل بانريست في آن واحد مع مضادات حيوية أو أي أدوية أخرى في الحالات التالية:</li><li>إذا كانت لديك حساسية للمضاد الحيوي أو الدواء الآخر الذي يمكن أن يصفه لك الطبيب مع بانريست.</li><li>إذا كنت تعاني من مرض متوسط الدرجة أو شديد بالكبد أو الكلى.</li><li>لا تستعمل بانريست في آن واحد مع اتازانافير (دواء مضاد للفيروسات).</li><li>لا تستعمل هذا الدواء بعد تاريخ إنتهاء صلاحيته المطبوع على العلبة ، فإذا تناولته بعد تاريخ إنتهاء الصلاحية فقد لا يعطي مفعوله بالدرجة المناسبة.</li><li>لا تستعمل هذا الدواء إذا كانت العبوة تالفة أو ممزقة أو بها أي مظاهر عبث أو كان مظهرها مشتبه فيه.</li><li>إذا كنت غير متأكد من ضرورة البدء في إستعمال هذا العلاج يجب عليك إستشارة الطبيب</li></ul><p>&nbsp;</p><p><strong><u>ب- التحذيرات والاحتياطات</u></strong></p><p dir="RTL">أوضحت التقارير الحديثة زيادة في عدد الحالات التي شخصت بالإسهال المصاحب لبكتيريا كلوستيريديوم ديفيسيل (سي دي إي دي) و ذلك للحالات التي تستخدم موانع مضخات البروتون المعدية سواء كانت سريرية أو غير سريرية. و مع ذلك بعض الدراسات لم تجد علاقة بين (سي دي إي دي) و استخدام موانع مضخات البروتون المعدية.</p><p dir="RTL">وجدت الدراسات التلاحظية علاقة بين (سي دي إي دي) و استخدام موانع مضخات البروتون المعدية . و ناقشت كل تلك الدراسات معدل الإصابة و نسبة التعرض ل (سي دي إي دي) في المرضى المستخدمين لموانع مضخات البروتون المعدية ، وكان من الواضح في بعض الدراسات وجود علاقة بينهما و البعض الاخر لم يجد علاقة .</p><p dir="RTL">إن مدة استخدام موانع مضخات البروتون المعدية ليس لها علاقة بظهور (سي دي إي دي).</p><p dir="RTL"><strong>ابحث عن العلاج إذا كنت من مستخدمي موانع مضخات البروتون المعدية و أصبت بإسهال لا يتحسن، قد يكون هذا نتيجة (سي دي إي دي). و لا تتوقف عن الدواء بدون الرجوع للطبيب . </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ت- الحمل والرضاعة</u></strong></p><p dir="RTL">بالنسبة للنساء إذا كانت تخطط للحمل أو ترضع الطفل، سوف يناقش معك الطبيب كافة المخاطر المحتملة و الفوائد المرجوة من استخدام بانريست أثناء الحمل أو الإرضاع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ث- الاحتياطات عند استعمال بانريست</u></strong></p><p dir="RTL"><strong>قبل البدء باستخدام هذا الدواء، اخبر طبيبك في أي من الحالات التالية:</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لأي من بانريست أو أي من المكونات الأخرى المذكورة في نهاية هذه النشرة أو أي مواد أخرى مثل الأطعمة أو المواد الحافظة أو الصبغات.</li><li>إذا كنت تعاني من أي مرض أو مشاكل صحية.</li></ul><p dir="RTL">يجب ألا تعطي هذا الدواء لأي شخص آخر حتى لو كانت أعراضه مشابهه لأعراضك. و لا تستعمل هذا الدواء لعلاج أعراض أو مشاكل أخرى ما لم يكن ذلك بناء على تعليمات الطبيب أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ج- تأثيره</u></strong><strong><u> على القيادة واستخدام الآلات</u></strong><strong><u>:</u></strong></p><p dir="RTL">يجب أن تتوخى الحذر أثناء قيادة السيارات أو تشغيل الآليات حتى تعرف كيف يؤثر عليك بانريست.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ح- التفاعلات مع هذا الدواء</u></strong></p><p dir="RTL">اخبر الطبيب أو الصيدلي عن أي أدوية أخرى تستعملها بما فيها تلك التي تشتريها بدون و صفة طبية.</p><p dir="RTL">هناك بعض الأدوية التي تتأثر ببانريست أو تؤثر في كيفية عمله أو مفعوله و تشمل هذه الأدوية بعض مضادات التجلط و بعض أنواع الأدوية التي تعتمد فعاليتها على مستوى الحموضة في المعدة مثل كيتوكونازول.</p><p dir="RTL">و يمكن أن يخيرك الطبيب أو الصيدلي إذا كان بإمكانك استعمال أي من تلك الأدوية، و يمكن أن يكون لديهم المزيد من المعلومات حول الأدوية التي ينبغي أن تتجنبها أو تتناولها بحرص و حذر أثناء استخدامك بانريست. قد تحدث بعض التأثيرات أو التفاعلات غير المذكورة أعلاه.</p><p dir="RTL">هناك بعض الإجراءات و التدابير التي يمكن أن تساعد في تحسين حالتك و نذكر بعضها أدناه . تحدث إلى الطبيب أو الصيدلي حول هذه الإجراءات ومن أجل الحصول على مزيد من المعلومات .</p><p dir="RTL"><strong><u>الكحول</u></strong>: قد ينصح الطبيب بتقليل تناول الكحول.</p><p dir="RTL"><strong><u>الأسبرين</u></strong>: و كثير من الأدوية الأخرى التي تستعمل لعلاج التهابات المفاصل و تسكين اللألم و الصداع قد تسبب التهيج و الإلتهابات في المعدة و قد تؤدي إلى تفاقم حالتك. و يمكن أن يصف لك الطبيب بعض الأدوية الأخرى كبدائل يمكنك استخدامها.</p><p dir="RTL"><strong><u>الكافيين</u></strong>: قد ينصحك الطبيب بالتقليل من تناول بعض المشروبات التي تحتوي على الكافين مثل القهوة و الشاي و الكاكاو و المياه الغازية (الكولا) حيث أنها تحتوي على مكونات يمكن أن تهيج المعدة.</p><p dir="RTL"><strong><u>العادات الغذائية</u></strong>: تناول وجبات صغيرة و عديدة. و عليك أن تأكل ببطء و تمضغ الطعام جيدا و لا تحاول أن تسرع في تناول الوجبات.</p><p dir="RTL"><strong><u>التدخين</u></strong>: قد ينصحك الطبيب بالامتناع عن التدخين أو على الأقل التخفيف منه.</p><p dir="RTL"><strong><u>الوزن</u></strong>: قد ينصحك الطبيب بتخفيف وزنك حيث أن ذلك يفيدك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اتبع جميع التعليمات التي يعطيها لك الطبيب أو الصيدلي بكل دقة. و قد تختلف تلك التعليمات عن المعلومات و الإرشادات الموجودة في هذه النشرة. و إذا لم تفهم أي تعليمات مكتوبة اسأل الطبيب أو الصيدلي ليوضحها لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>أ- ماهو المطلوب استخدامه من بانريست</u></strong></p><p dir="RTL">الجرعة المعتادة هي قرص واحد يوميا. و لكن إذا وصف لك الطبيب أيضا مضادات حيوية جنبا إلى جنب مع مضادات الحموضة لعلاج قرحات الإثنى عشر فإن جرعة بانريست ستكون 40 ملجم يوميا. و يجب تناول أول جرعة في الصباح و اعتبارا من الجرعة الثانية فإنها تؤخذ قبل الوجبة المسائية لمدة 7 أيام.</p><p dir="RTL">و إن الطبيب سوف يصف لك الجرعة المناسبة، و تعتمد كل من الجرعات و معدل تكرارها و مدة الإستعمال على الحالة الصحية لكل مريض على حدة. و قد يقوم الطبيب بتغيير الجرعة عند حدوث تغير في حالتك الصحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ب- كيف يستخدم بانريست ومتى</u></strong></p><p dir="RTL">يجب ابتلاع الأقراص كاملة كما هي مع قليل من الماء و مع أو بدون طعام.<strong> لا تسحق الأقراص أو تمضغها فإن أقراص بانريست مغلفة بغلاف يحميها من أحماض المعدة و يجب أن لا يتلف هذا الغلاف حتى يعمل بانريست بفعالية.</strong></p><p dir="RTL">و إذا كنت تتناول أدوية أخرى مع بانريست مثل المضادات الحيوية فيجب أن تتبع التعليمات الخاصة بكل دواء بدقة.</p><p dir="RTL">يجب تناول الدواء في نفس الوقت من كل يوم فإن ذلك سيحقق أفضل مفعول للدواء و هذا يساعد أيضا على تذكر تناول الدواء في الوقت نفسه من كل يوم.</p><p dir="RTL">يجب الإستمرار في تناول الدواء حسب المدة التي يحددها الطبيب و احرص على أن يتوفر لديك مخزون يكفي لأيام الإجازات و عطلات نهاية الإسبوع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ت- الجرعة الزائدة</u></strong></p><p dir="RTL">إذا تناولت جرعة زائدة عليك إبلاغ الطبيب أو مركز معلومات السموم فوراً، أو اذهب مباشرة إلى قسم الطوارئ في أقرب مستشفى، و عليك القيام بذلك حتى لو لم تظهر أي اعراض للتسمم أو المضايقة، فقد تكون بحاجة إلى رعاية طبية عاجلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ث- الجرعة الفائتة</u></strong></p><ul dir="rtl"><li>إذا كان الوقت قد حان لتناول الجرعة التالية يجب عليك تناول الجرعة التالية و تهمل الجرعة التي نسيتها. و إلا فيجب عليك أن تتناول الجرعة التي نسيتها في أسرع وقت عندما تتذكرها ثم تواصل تناول الجرعات التالية في أوقاتها الأصلية. لا تتناول جرعة مضاعفة لتعويض تلك التي نسيتها فإن ذلك يزيد من فرص حدوث آثار جانبية. و إذا كانت لديك مشكلة في تذكر أوقات الجرعات، اطلب من الصيدلي تزويدك ببعض الإرشادات التي تساعدك في التغلب على هذه المشكلة.</li><li>لا تتوقف عن استعمال هذا الدواء أو تغير جرعاته بدون استشارة الطبيب.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>ح- عند استخدام بانريست</u></strong></p><p dir="RTL">يجب عليك تناول بانريست بنفس الجرعات التي حددها الطبيب تماماً. و بالنسبة للمرأة يجب إبلاغ الطبيب إذا حملت آثناء استعمالها بانريست. ويجب ابلاغ جميع الأطباء و المعالجين الذين يقدمون لك الرعاية الصحية بأنك تستعمل بانريست. و إذا استعملت بانريست لفترة طويلة (ما يزيد عن سنة مثلا) عليك مراجعة الطبيب لكي يتولى الإشراف عليك و مراقبة حالتك. أخبر الطبيب إذا كنت لا تشعر بتحسن من جراء تناول بانريست فقد يقوم بإجراء المزيد من الفحوصات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>عليك إبلاغ الطبيب أو الصيدلي إذا شعرت ببعض الضيق أو عدم الإرتياح أثناء تناول بانريست حتى لو كنت تعتقد أن تلك الآثار ليس لها علاقة بتناول بانريست و حتى لو كانت غير مذكورة في هذه النشرة.</strong></p><p dir="RTL">و كما هي الحال في غيره من الأدوية قد يسبب بانريست بعض التأثيرات الجانبية و التي إذا حدثت فإنها غالبا تكون طفيفة و مؤقتة.</p><p dir="RTL">و لكن بعضها قد يكون خطيرا و يستدعي العناية الطبية. وإن الطبيب الذي وصف لك الدواء قد وازن ما بين الفوائد المرجوة و المخاطر المحتملة من جراء استخدامه.</p><p>&nbsp;</p><p><u><strong>حالات نقص ماغنيسيوم</strong></u></p><p dir="RTL">سجلت حالات نقص ماغنيسيوم نادرة أثناء استخدام العقارلمدة طويلة لا تقل عن ثلاثة أشهر، و لكن غالبية الحالات التي&nbsp; سجل فيها نقص الماغنيسيوم حدثت&nbsp; بعد مرور سنة. وتكون الحالات عرضية أو لاعرضية، و في حالة الإصابة الشديدة ربما يؤدي نقص الماغنيسيوم إلى نوبات صرعية و عدم انتظام نبضات القلب.&nbsp; يأخذ المريض سيرم ماغنيسيوم قبل البدء في استخدام بانريست خصوصاً إذا كان المريض يأخذ عقارات مثل ديجوكسين، مدرات البول أو أي عقارات أخرى متعارف أنها تسبب نقص الماغنيسيوم، ولذلك فإن علاج نقص الماغنيسيوم يكون عن طريق التعويض بالماغنيسيوم مع ضرورة التوقف عن الإستمرار في استخدام بانريست. و يعود تركيز الماغنيسيوم في الدم إلى معدله الطبيعي بعد إسبوع من التوقف عن استخدام بانريست.</p><p dir="RTL">تحدث مع الطبيب أو الصيدلي عن أي تساؤلات أو هواجس تتعلق باستعمال هذا الدواء.</p><p dir="RTL">و فيما يلي نورد الآثار الجانبية المحتملة. لا تنزعج من هذه الآثار الجانبية فقد لا تشعر بأي منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أبلغ الطبيب أو الصيدلي عندما تلاحظ أي من الأعراض التالية:</strong></p><ul dir="rtl"><li>الصداع</li><li>الدوار</li><li>الإسهال</li><li>الغثيان أو القئ</li><li>ألم بالمعدة</li><li>زيادة في الغازات بالمعدة أو الأمعاء</li><li>عسر هضم</li><li>الإمساك</li><li>جفاف الفم</li><li>طعم معدني بالفم</li><li>ضعف أو إعياء</li><li>زيادة التعرق</li><li>زغللة في النظر</li><li>مشاكل في الجلد مثل الحكة أو الطفح الجلدي</li></ul><p dir="RTL">الأعراض المذكورة أعلاه هي الآثار الجانبية الأكثر شيوعا للبانريست. و بعض تلك الأعراض يمكن أن تكون نتيجة الجمع ما بين بانريست و أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أبلغ الطبيب أو الصيدلي عندما تلاحظ أي من الأعراض التالية:</strong></p><ul dir="rtl"><li>غثيان، قئ، فقدان الشهية، الشعور العام بالضيق، حمى، حكة اصفرار الجلد و العيون، تغير لون البول إلى اللون الغامق.</li><li>مشاكل في الجلد مثل الحكة أو الطفح الجلدي أو التورم أو تقشر الجلد.</li><li>تورم الوجه أو الشفتين أو الفم أو اللسان أو الحلق مما قد يسبب صعوبات في البلع أو التنفس.</li><li>التهاب (عدوى) متكرره قد تظهر على شكل حمى أو نوبات قشعريرة شديدة أو التهاب الحلق أو قروح بالفم.</li><li>ألم بالصدر.</li><li>ضيق بالتنفس.</li><li>ارتفاع ضغط الدم.</li><li>تورم الرجلين.</li><li>حدوث نزيف أو كدمات بسهولة أكثر من المعتاد.</li><li>إكتئاب أو إرتباك أو قلق.</li></ul><p dir="RTL">فقد تكون تلك الأعراض من الآثار الجانبية الخطيرة مما قد يستدعي عناية طبية عاجلة. و لكن بشكل عام فإن الآثار الجانبية الخطيرة نادرة. و قد تحدث لدى بعض الأشخاص آثار جانبية لم تذكر هنا، و يجب إبلاغ الطبيب عن أي أعراض تلاحظها عند استعمال الدواء أو بعد الإنتهاء من استعماله. <strong>اسأل الطبيب أو الصيدلي عن أي شئ لا تفهمه من المعلومات الواردة في هذه النشرة.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li><strong>يحفظ&nbsp; بعيدًا عن متناول الأطفال.</strong></li><li>يفضل أن يوضع في خزانة ذات قفل مثبتة على ارتفاع متر و نصف عن الأرض على الأقل.</li><li>يخزن في عبوته الأصلية حتى موعد اخذ الدواء و لا يجب تركه مفتوحاً او إخراج الاقراص خارج العلبة.</li><li>يخزن في عبواته الأصلية في جو بارد و جاف و في درجة حرارة أقل من 30 درجة مئوية.</li><li>لا تخزن هذا الدواء أو أي دواء آخر في الحمام أو قرب الحوض و لا تتركه قرب النافذة أو داخل السيارة.</li><li>الحرارة الزائدة و الرطوبة يمكن أن تؤدي إلى تلف بعض الأدوية.</li><li><strong>التخلص من بقايا الدواء: </strong>إذا طلب منك الطبيب أو الصيدلي التوقف عن استعمال الدواء أو أن تاريخ صلاحيته انتهى ينبغي أن تسأل الطبيب أو الصيدلي عن طريقة التخلص من الدواء المتبقي.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="RTL">المادة الفعالة هي بانتوبرازول الصوديوم.</li><li dir="RTL">باقي المواد هي لاكتوز، مانيتول، كروسوبوفيدون، سيليولوز متبلور دقيق، ستياريت المغنيسيوم،هيبروميلوز، بولي إيثيلين جليكول 8000، كربونات صوديوم لا مائية، حامض ميثاكريليك، بوليمر مشترك نوع &ndash; سي، ثلثي إيثيل سترات، تالك، ثاني أكسيد التيتانيوم، أكسيد الحديد الأصفر.</li></ul><p dir="RTL">هذا الدواء خالي من الجلوتين و السكروز و التارترازين و غيرها من صبغات الآزو.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوفر الأقراص بعيار 20 و 40 ملجم &nbsp;و هي مزودة &nbsp;بغلاف مقاوم للأحماض يسمى التغليف المعوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>أقراص 20 ملجم:</u></strong></p><p dir="RTL">هي أقراص بيضاوية بلون أصفر محفور على أحد جانبيها الحروف (APO) و الرمز&nbsp; (P20) على الجانب الآخر. و هي متوفرة في عبوات شرائح &nbsp;بليستر 30 قرص و في قوارير سعة 30 و 100 و 500 قرص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>أقراص 40 ملجم:</u></strong></p><p dir="RTL">هي أقراص بيضاوية بلون أصفر محفور على أحد جانبيها الحروف (APO) و الرمز (P40) على الجانب الآخر.</p><p dir="RTL">وهي متوفرة في عبوات شرائح &nbsp;بليستر 30 قرص و في قوارير سعة 30 و 100 و 500 قرص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">* قد لا يتم تسويق كل التراكيز والاحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة ابوتكس، في مدينة تورنتو، مقاطعة اونتاريو،M9L 1T9 &nbsp;كندا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PANREST,
Pantoprazole enteric-coated tablets 20 mg and 40 mg. 
Pantoprazole sodium sesquihydrate.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Enteric coated tablets intended for oral administration.
Composition
Pantoprazole sodium, lactose, mannitol, crospovidone, microcrystalline cellulose, magnesium stearate, hypromellose, polyethylene glycol 8000, anhydrous sodium carbonate, methacrylic acid Copolymer type C, triethyl citrate, talc titanium dioxide, iron oxide yellow.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Panrest Tablets 20 mg

Yellow, oval, biconvex, enteric-coated tablets engraved “APO” on one side, “20” on the other side. Blisters (Alu/Alu) of 30 tablets and bottles of 30, 100 and 500 tablets.

Panrest Tablets 40 mg

Yellow, oval, biconvex, enteric-coated tablets engraved “APO” on one side, “40” on the other side. Blisters (Alu/Alu) of 5 and 30 tablets and bottles of 30, 100 and 500 tablets.

* Not all packs available.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic improvement and healing of the following gastrointestinal diseases which require a reduction in acid secretion:</p><ul><li>Duodenal ulcer.</li><li>Gastric ulcer.</li><li>Gastroesophageal reflux disease (GORD). Symptomatic GORD: the treatment of heartburn and other symptoms associated with GORD.</li><li>Reflux oesophagitis.</li><li>Gastrointestinal lesions refractory to H 2-blockers.</li><li>Zollinger-Ellison syndrome.</li></ul><p>&nbsp;</p><p>Patients whose gastric or duodenal ulceration is not associated with ingestion of NSAIDs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.</p><p>Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.</p><p>For eradication of <em>Helicobacter pylori, </em>treatment with pantoprazole and one of the following combinations of antibiotics: clarithromycin and amoxycillin or clarithromycin and metronidazole or amoxycillin and metronidazole is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism (see <strong>DOSAGE AND ADMINISTRATION</strong>).</p><p>Pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of <em>H. pylori </em>associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism.</p><p>Prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective NSAIDs in increased risk patients with a need for continuous nonselective NSAID treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole tablets should not be chewed or crushed, but swallowed whole with a little water.</p><p>&nbsp;</p><p><strong><em>Helicobacter</em></strong><strong><em> </em></strong><strong><em>pylori</em></strong><strong><em> </em></strong><strong>Positive</strong><strong> </strong><strong>Patients</strong></p><p>In <em>H. pylori </em>positive patients with gastric and duodenal ulcers, eradication of this microorganism by combination therapy should be achieved. One of the following combinations of pantoprazole with antibiotics is effective.</p><ul><li>Pantoprazole 40 mg twice daily plus amoxycillin 1,000 mg (2 x 500 mg) twice daily plus clarithromycin 500 mg twice daily.</li><li>Pantoprazole 40 mg twice daily plus metronidazole 400 mg in the morning and 600 mg at night plus clarithromycin 500 mg twice daily.</li><li>Pantoprazole &nbsp;40 &nbsp;mg &nbsp;twice &nbsp;daily &nbsp;plus &nbsp;amoxycillin &nbsp;1,000 &nbsp;mg &nbsp;(2 &nbsp;x &nbsp;500 &nbsp;mg) &nbsp;twice &nbsp;daily &nbsp;plus metronidazole 400 mg in the morning and 600 mg at night.</li><li>Pantoprazole 40 mg twice daily plus bismuth subcitrate 108 mg four times a day plus metronidazole</li></ul><p>200 mg three times&nbsp;a&nbsp;day and 400 mg at night plus tetracycline 500 mg (2 x 250 mg) four times a day.</p><p>In combination therapy for eradication of <em>H. pylori </em>infection, the second tablet should be taken before the evening meal.</p><p>The duration for combination therapy is seven days. If further treatment with pantoprazole is indicated to ensure ulcer healing, dosage recommendations as listed below for duodenal and gastric ulcers should be followed.</p><p>&nbsp;</p><p><strong><em>Helicobacter</em></strong><strong><em> </em></strong><strong><em>pylori</em></strong><strong><em> </em></strong><strong>Negative</strong><strong> </strong><strong>Patients</strong></p><p>In <em>H. pylori </em>negative patients,The following dosage guidelines apply for monotherapy with pantoprazole:</p><p>&nbsp;</p><p><strong>Duodenal Ulcer</strong></p><p>Pantoprazole 40 mg (one tablet) should be given once a day. In most patients, freedom from symptoms is achieved rapidly and healing generally occurs within two weeks. If a two week period of treatment is not sufficient, healing will be achieved in almost all cases within a further two weeks.</p><p>&nbsp;</p><p><strong>Gastric Ulcer</strong></p><p>Pantoprazole 40 mg (one tablet) should be given once a day. In most patients, freedom from symptoms is achieved rapidly and healing usually takes four weeks. If a four week period of treatment is not sufficient, healing will usually be achieved in a further four weeks.</p><p>&nbsp;</p><p><strong>Lesions Refractory to H2-Receptor Antagonists</strong></p><p>Pantoprazole 40 mg (one tablet) should be given once a day. In most patients, freedom from symptoms is achieved rapidly and healing usually takes four weeks. If a four week period of treatment is not sufficient, healing is achieved in the majority of patients in a further four weeks. In a small group of patients, there may be benefit in extending pantoprazole therapy to a total of 12 weeks.</p><p>&nbsp;</p><p><strong>Zollinger-Ellison Syndrome</strong></p><p>The number of pantoprazole 40 mg tablets should be individually adjusted, so that the acid output remains below 10 mmol/L. No fixed period of time is proposed for treatment of Zollinger-Ellison syndrome.</p><p>&nbsp;</p><p><strong>Gastroesophageal Reflux Disease</strong></p><p><u>Symptomatic Gastroesophageal Reflux Disease (Treatment of Symptomatic Reflux)</u></p><p>The recommended dosage is one pantoprazole 20 mg tablet/day. If symptom control has not been achieved after four weeks treatment with pantoprazole 20 mg tablets daily, further investigation is recommended, for example, endoscopy.</p><p>&nbsp;</p><p><u>Treatment of Reflux Oesophagitis</u></p><p>The recommended oral dosage is one pantoprazole 20 or 40 mg tablet/day. A four week period is usually required for healing, however, if this is not sufficient, healing will usually be achieved within a further four weeks. This dosage may be increased up to pantoprazole 80 mg/day.</p><p>&nbsp;</p><p><u>Maintenance of Healed Reflux Oesophagitis in Patients Previously Treated for Moderate to Severe Reflux</u> <u>Oesophagitis</u></p><p>For long-term management, a maintenance dose of one pantoprazole 20 or 40 mg tablet/day is recommended, dependent upon patient response.</p><p>&nbsp;</p><p><u>Prevention of Gastroduodenal Lesions and Dyspeptic Symptoms Associated with Non-Selective Non-</u> <u>Steroidal Anti-Inflammatory Drugs in Increased Risk Patients with a Need for Continuous Non-Selective</u> <u>Non-Steroidal Anti-Inflammatory Drug Treatment</u></p><p>The recommended oral dosage is one pantoprazole 20 mg tablet/day.</p><p>&nbsp;</p><p><strong>Use in Children</strong></p><p>There are no data currently available on the use of pantoprazole in children.</p><p>&nbsp;</p><p><strong>Use in the Elderly</strong></p><p>The usual daily dose of 20 or 40 mg can be given. During combination therapy for the eradication of <em>H. pylori, </em>elderly patients should receive the recommended pantoprazole dose of 40 mg twice daily for a one week treatment period.</p><p>&nbsp;</p><p><strong>Impaired Renal Function</strong></p><p>The usual daily dose of 20 or 40 mg can be given. Combination therapy for eradication of <em>H. pylori </em>should not be used in patients with moderate to severe renal dysfunction as no data are available on efficacy and safety in this population.</p><p>&nbsp;</p><p><strong>Impaired Hepatic Function</strong></p><p>Combination therapy for eradication of <em>H. pylori </em>should not be used in patients with moderate to severe hepatic dysfunction as no data are available on efficacy and safety in this population.</p><p>Pantoprazole is contraindicated in patients with cirrhosis or severe liver disease (see CONTRAINDICATIONS).</p><p>With milder forms of liver disease, the minimum effective dose has not been determined and the initial dose should be reduced.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to any components of the formulation; cirrhosis or severe liver disease.
 
Combination therapy for eradication of H. pylori is contraindicated in patients with known hypersensitivity to any of the antibiotics proposed for combination therapy for eradication of H. pylori or in patients with moderate to severe hepatic or renal dysfunction. The product information for the individual components of the combination H. pylori eradication therapy should be consulted for any further contraindications.

Pantoprazole, like other proton pump inhibitors, should not be coadministered with atazanavir (see Interactions).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Check the Following Before Use:</u></p><p>In the case of combination therapy for the eradication of <em>H. pylori, </em>the product information for the antibiotics used in the combination should be observed. In the presence of any alarm symptoms (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis, anaemia or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with pantoprazole may alleviate symptoms and delay diagnosis. Further investigation is to be considered if symptoms persist despite adequate treatment.</p><p>Pantoprazole, as all acid blocking medicines, may reduce the absorption of cyanocobalamin (vitamin B12) due to hypochlorhydria or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy and in patients with Zollinger-Ellison syndrome and other pathological hypersecretory conditions requiring long-term treatment if respective clinical symptoms are observed. Rare cases of cyanocobalamin deficiency following acid blocking therapy have been reported.</p><p>Use of pantoprazole 20 mg for prevention of gastroduodenal lesions and dyspeptic symptoms associated with nonselective NSAIDs should be restricted to patients who require continued nonselective NSAID treatment and have an increased risk of developing gastrointestinal complications. The increased risk should be assessed according to individual risk factors, e.g. high age (&gt; 65 years), history of gastric or duodenal ulcer or upper gastrointestinal bleeding.</p><p>&nbsp;</p><p><u>Monitoring</u></p><p>In long-term treatment, especially when exceeding a treatment period of one year, patients should be kept under regular surveillance.</p><p>Patients being treated for symptomatic GORD with pantoprazole 20 mg who do not respond after four weeks should be investigated.</p><p>&nbsp;</p><p><strong>General Toxicity</strong></p><p><u>Gastrointestinal System</u></p><p>Treatment with pantoprazole causes dose dependent hypergastrinaemia as a result of inhibition of gastric acid secretion. Gastrin has a trophic effect on the gastric mucosa, and increases in gastric weight have been observed in rats and dogs to be dependent upon both dose and duration of treatment. Accompanying histopathological changes in the gastric mucosa were increased height, dilatation of fundic glands, chief cell hyperplasia and/or atrophy and parietal cell hyperplasia or vacuolation/ degeneration. Increased density of enterochromaffin-like (ECL) cells was observed after 12 months treatment at dose levels from 5 mg/kg/day in rats and 2.5 mg/kg/day in dogs; all changes were reversible after various recovery periods. Since these gastric effects are a consequence of the pharmacological effect of acid secretion inhibition, no effect doses were not established in all instances.</p><p>Although rats might be more susceptible to this effect than other species because of their high ECL cell density and sensitivity to gastrin, ECL cell hyperplasia occurs in other species, including mice and dogs, and has been observed in one of two clinical trials in which ECL cell density was measured (a two-fold increase was observed in study RR126/97 after up to five years of treatment with regular and high doses, but no increase was observed in study RR125/97). No dysplastic or neoplastic changes were observed in gastric endocrine cells in either study.</p><p>&nbsp;</p><p><u>Ocular Toxicity and Dermal Phototoxicity/Sensitivity</u></p><p>Studies have shown that pantoprazole is retained in low levels in the eyes and skin of pigmented rats. It is likely that the retention reflects a reversible association with melanin. Animal studies investigating the potential for phototoxicity/ photosensitivity have not been conducted.</p><p>A two week dog study, conducted specifically to investigate the effects on the eye and ear, did not reveal any changes relating to pantoprazole treatment, but the doses chosen were relatively low (40 and 160 mg (about 4 and 15 mg/kg) orally and 60 mg (about 6 mg/kg) IV). No ophthalmological changes or changes in electroretinographs were observed in cynomolgus monkeys at IV doses of up to 15 mg/kg/day for four weeks.</p><p>&nbsp;</p><p><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility</strong></p><p><u>Genotoxicity</u></p><p>A number of <em>in vitro </em>and <em>in vivo </em>genotoxicity assays covering mutagenicity, clastogenicity and DNA damage endpoints were conducted on pantoprazole and the results were generally negative. Exposures achieved in the <em>in vivo </em>tests in mice and rats were well in excess of exposures expected clinically. However, pantoprazole was clearly positive in carefully conducted cytogenetic assays in human lymphocytes <em>in vitro, </em>both in the presence and absence of metabolic activation. Omeprazole was also positive in a comparable test conducted in the same laboratory, suggesting a possible class effect. A minute amount of radioactivity was bound to rat hepatic DNA after treatment with pantoprazole 200 mg/kg/day for 14 days. However, no distinct DNA adduct has been detected.</p><p>&nbsp;</p><p><u>Mutagenesis</u></p><p>Pantoprazole was found to be negative in the following studies: <em>in vivo </em>chromosome aberration assay in rat and bone marrow (126E/95), mouse lymphoma test (222E/95) and a gene mutation test in Chinese hamster ovary cells <em>(in vitro) </em>(188E/95). In addition, toxicokinetic studies were conducted in rats at the doses used in the bone marrow assay (50 to 1,200 mg/kg) (56E/96) and in mice at the high dose from the earlier micronucleus test (710 mg/kg) (89E/96). In both species, pantoprazole exposure was high with the AUCs being 26 to 30 times higher in the rat or mouse, respectively, than in humans using the 20 mg tablet.</p><p>&nbsp;</p><p><u>Carcinogenicity</u></p><p>A two year oral carcinogenicity study in Sprague-Dawley rats at doses up to 200 mg/kg/day showed gastric carcinoids after pantoprazole treatment at doses greater than 0.5 mg/kg/day in females and greater than 5 mg/kg/day in males, with none observed in controls. The development of gastric tumours is attributed to chronic elevation of serum gastrin levels with associated histopathological changes in the gastrointestinal system. In both male and female rats the development of hepatocellular adenomas was increased at doses greater than 5 mg/kg/day and development of hepatocellular carcinomas was increased at doses greater than 50 mg/kg/day. Hepatocellular tumours, which were also observed in female mice at oral doses greater than 25 mg/kg/day, may be associated with pantoprazole induced increases in hepatic enzyme activity.</p><p>Treatment with pantoprazole at doses greater than 50 mg/kg/day also increased the development of thyroid follicular cell adenomas in male and female rats. Several studies in rats were conducted to investigate the effect of pantoprazole on the thyroid, the results of which suggested that the effect may be secondary to the induction of enzymes in the liver.</p><p>In a more recent carcinogenicity study, Fischer rats were studied using lower doses (5, 15 and 50 mg/kg). Gastric carcinoids were detected at all doses in females and at the 15 and 50 mg/kg doses in males, and none were detected in controls. No metastases of these carcinoids were detected. There was no increase in the incidence of liver tumours. The dose of 15 mg/kg is seen to be the no effect level for liver tumours in rodents. Consideration of the possible mechanisms involved in the development of the above drug related tumour types suggests that it is unlikely that there is any carcinogenic risk in humans at therapeutic dose levels of pantoprazole for short-term treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole is metabolised in the liver via the cytochrome P450 enzyme system. A study using human liver microsomes suggested that the P450 enzymes CYP2C19 and CYP3A4 are involved in its metabolism. In addition, CYP2D6 and CYP2C9-10 were implicated in another study. An interaction of pantoprazole with other drugs or compounds which are metabolised using the same enzyme system cannot be excluded. However, no clinically significant interactions were observed in specific tests with a number of such drugs or compounds, namely carbamazepine, caffeine, diazepam, diclofenac, digoxin, ethanol, glibenclamide, metoprolol, naproxen, nifedipine, phenytoin, piroxicam, theophylline and the low dose oral contraceptive Triphasil (levonorgestrel and ethinyloestradiol). There was also no interaction with a concomitantly administered antacid (aluminium hydroxide and magnesium hydroxide).</p><p>Although no interaction during concomitant administration of phenprocoumon or warfarin has been observed in clinical pharmacokinetic studies, a few isolated cases of changes in international normalised ratio (INR) have been reported during concomitant treatment in the postmarketing period. Therefore, in patients being treated with coumarin anticoagulants, monitoring of prothrombin time/ INR &nbsp;is recommended after initiation, termination or during irregular use of pantoprazole.</p><p>Treatment of dogs with IV famotidine shortened the duration of the pH elevation effect of pantoprazole.</p><p>As with all acid suppressant medications, the absorption of drugs whose bioavailability is pH dependent (e.g. ketoconazole) might be altered due to the decrease in gastric acidity.</p><p>Four crossover pharmacokinetic studies designed to examine any interactions between pantoprazole and the drugs clarithromycin, amoxycillin and metronidazole, conducted in 66 healthy volunteers, showed no interactions.</p><p>It has been shown that coadministration of atazanavir 300 mg/ ritonavir 100 mg with omeprazole (40 mg once daily) or atazanavir 400 mg with lansoprazole (60 mg single dose) to healthy volunteers resulted in a substantial reduction in the bioavailability of atazanavir. The absorption of atazanavir is pH dependent. Therefore, proton pump inhibitors, including pantoprazole, should not be coadministered with atazanavir (see <strong>CONTRAINDICATIONS</strong>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effects on Fertility</strong></p><p>Pantoprazole at oral doses up to 500 mg/kg/day in male rats and 450 mg/kg/day in female rats (estimated exposure at least 60-fold the clinical exposure from the 40 mg tablet) was found to have no effect on fertility and reproductive performance.</p><p>&nbsp;</p><p><strong>Use in Pregnancy (Category B)</strong></p><p>Teratological studies in rats and rabbits gave no evidence of a teratogenic potential for pantoprazole. In oral studies in rats, dose dependent toxic effects were observed on fetuses and pups: increased prenatal and postnatal deaths (450 mg/kg/day), reduced fetal weight (greater than or equal to 150 mg/kg/day) and delayed skeletal ossification and reduced pup growth (greater than or equal to 15 mg/kg/day). For the latter, a no effect dose was not established. Doses of 450 mg/kg/day were maternotoxic and may have been associated with dystocia and incomplete parturition. Penetration of the placenta was investigated in the rat and was found to increase with advanced gestation. As a result, concentrations of pantoprazole in the foetus are increased shortly before birth regardless of the route of administration. The significance of these findings in humans is unclear. As there is no information on the safety of the drug during pregnancy in women, pantoprazole should not be used during pregnancy unless the benefit clearly outweighs the potential risk to the foetus.</p><p>&nbsp;</p><p><strong>Use in Lactation</strong></p><p>A perinatal/postnatal study in rats found that treatment with pantoprazole at doses of 10 mg/kg/day or greater decreased pup growth. A transient effect on one of a series of development tests (startle response) was only evident in the 30 mg/kg/day group at an age when male and female offspring showed lower bodyweights, paralleled with lower brain weight, than the controls. The significance&nbsp; of &nbsp;these findings for humans is unknown, and there is currently no information on the safety of pantoprazole during breastfeeding in humans. Therefore, pantoprazole should only be used during lactation if the benefits clearly outweigh the risks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No or negligible influence.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole is well tolerated. Most of the adverse reactions seen&nbsp; with&nbsp; treatment&nbsp; were&nbsp; of&nbsp; mild&nbsp; or moderate intensity. The following adverse reactions have been reported in patients receiving pantoprazole alone or in combination with antibiotics for <em>H. pylori </em>eradication in clinical trials and postmarketing surveillance.</p><p>&nbsp;</p><p><strong>Body as a Whole</strong></p><p>Fatigue, asthenia and increased sweating.</p><p>Rare reports of fever, anaphylactic reactions including anaphylactic shock and peripheral oedema.</p><p>Very rare reports of substernal chest pain and hot flushes.</p><p>&nbsp;</p><p><strong>Cardiovascular Disorders, General</strong></p><p>Rare reports of hypertension.</p><p>Very rare reports of circulatory collapse.</p><p>&nbsp;</p><p><strong>Central and Peripheral Nervous System Disorders</strong></p><p>Headache.</p><p>Uncommon reports of dizziness.</p><p>Very rare reports of reduced movement and speech disorder.</p><p>&nbsp;</p><p><strong>Gastrointestinal System Disorders</strong></p><p>Diarrhoea, severe eructation, constipation or flatulence, dry mouth and upper abdominal pain.</p><p>Uncommon reports of nausea and vomiting.</p><p>Rare reports of rectal disorder and colonic polyp.</p><p>Very rare reports of faecal discolouration and increased saliva.</p><p>&nbsp;</p><p><strong>Hearing and Vestibular Disorders</strong></p><p>Very rare reports of tinnitus.</p><p>&nbsp;</p><p><strong>Liver and Biliary System Disorders</strong></p><p>Very rare reports of increased liver enzymes (transaminases, gamma-GT), hepatic failure, cholestatic hepatitis, bilirubinaemia and jaundice.</p><p>The occurrence of severe hepatocellular damage leading to jaundice or hepatic failure having a temporal relationship to the intake of pantoprazole has been reported with a frequency of approximately one in a million patients.</p><p>&nbsp;</p><p><strong>Metabolic and Nutritional Disorders</strong></p><p>Rare reports of hypertriglyceridaemia.</p><p>&nbsp;</p><p><strong>Hypomagnesaemia:</strong></p><p>Reported rarely usually with prolonged PPI use of &gt;3 months (most cases&gt;1 year of therapy ) may be symptomatic or asymptomatic ; severe cases may cause tetany seizures , and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesaemia; and periodically thereafter. Hypomagnesaemia may be corrected by magnesium supplementation, although discontinuation of pantoprazol may be necessary; magnesium levels typically return to normal within 1 week of stopping.</p><p>&nbsp;</p><p><strong>Musculoskeletal</strong></p><p>Rare reports of myalgia and arthralgia.</p><p>Very rare reports of pain including skeletal pain.</p><p>&nbsp;</p><p><strong>Renal and Urinary Disorders</strong></p><p>Very rare reports of interstitial nephritis.</p><p>&nbsp;</p><p><strong>Platelet, Bleeding, Clotting Disorders</strong></p><p>Very rare reports of thrombocytopenia and increased coagulation time.</p><p>&nbsp;</p><p><strong>Psychiatric Disorders</strong></p><p>Rare reports of onset of depression, hallucination, disorientation and confusion, especially in predisposed patients, as well as aggravation of these symptoms in the case of pre-existence.</p><p>Very rare reports of anxiety.</p><p>&nbsp;</p><p><strong>Red and white blood cell disorders</strong></p><p>Rare reports of anaemia.</p><p>Very rare reports of leucopenia.</p><p>&nbsp;</p><p><strong>Resistance mechanism disorders</strong></p><p>Rare reports of sepsis.</p><p>&nbsp;</p><p><strong>Respiratory system disorders</strong></p><p>Very rare reports of dyspnoea.</p><p>&nbsp;</p><p><strong>Skin and appendages</strong></p><p>Uncommon reports of allergic reactions such as pruritus and skin rash.</p><p>Very rare reports of angioedema, urticaria,,severe skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, Lyell syndrome and photosensitivity.</p><p>&nbsp;</p><p><strong>Special senses, other disorders</strong></p><p>Metallic taste.</p><p>Very rare reports of changes to the senses of smell and taste.</p><p>&nbsp;</p><p><strong>Vascular (extracardiac) disorders</strong></p><p>Very rare reports of flushing.</p><p>&nbsp;</p><p><strong>Vision disorders</strong></p><p>Uncommon reports of disturbances in vision (blurred vision).</p><p>Very rare reports of conjunctivitis.</p><p>See Tables 1 and 2.</p><p>&nbsp;</p><p><strong>Pantoprazole Table 1</strong></p><p>Incidence (%) of Common (&gt; 1%) and Uncommon (&lt; 1%) Adverse Events in Clinical Trials of Triple Therapy Containing Pantoprazole in Combination with Two Antibiotics for <em>H.pylori </em>Eradication</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>&nbsp;</p><p>&nbsp;</p><p>Event</p></td><td colspan="3"><p><strong>Incidence</strong></p></td></tr><tr><td><p><strong>PCM/T* </strong></p><p><strong>(n = 725)</strong></p></td><td><p><strong>PAC</strong><strong> </strong></p><p><strong>(n</strong><strong> = 492)</strong></p></td><td><p><strong>PAM</strong><strong> </strong></p><p><strong>(n</strong><strong> = 146)</strong></p></td></tr><tr><td><p>Diarrhoea</p></td><td><p>4.8</p></td><td><p>10.0</p></td><td><p>7.5</p></td></tr><tr><td><p>Bitter taste</p></td><td><p>4.0</p></td><td><p>3.0</p></td><td><p>0</p></td></tr><tr><td><p>Nausea</p></td><td><p>3.7</p></td><td><p>1.2</p></td><td><p>1.4</p></td></tr><tr><td><p>Metallic taste</p></td><td><p>2.1</p></td><td><p>0.2</p></td><td><p>0</p></td></tr><tr><td><p>Upper abdominal pain</p></td><td><p>1.9</p></td><td><p>1.4</p></td><td><p>0</p></td></tr><tr><td><p>Headache</p></td><td><p>1.8</p></td><td><p>1.8</p></td><td><p>0</p></td></tr><tr><td><p>Dizziness</p></td><td><p>1.4</p></td><td><p>0.6</p></td><td><p>0</p></td></tr><tr><td><p>Tongue pain</p></td><td><p>1.2</p></td><td><p>0.8</p></td><td><p>0</p></td></tr><tr><td><p>Liver enzymes increased</p></td><td><p>1.2</p></td><td><p>0.2</p></td><td><p>0</p></td></tr><tr><td><p>Tiredness</p></td><td><p>1.1</p></td><td><p>0</p></td><td><p>0.7</p></td></tr><tr><td><p>Loose stools</p></td><td><p>1.0</p></td><td><p>0.8</p></td><td><p>0</p></td></tr><tr><td><p>Oral moniliasis</p></td><td><p>1.0</p></td><td><p>0.4</p></td><td><p>0</p></td></tr><tr><td><p>Buccal inflammation</p></td><td><p>1.0</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>Exanthemata</p></td><td><p>0.4</p></td><td><p>1.2</p></td><td><p>0.7</p></td></tr><tr><td><p>Heartburn</p></td><td><p>0.4</p></td><td><p>0.4</p></td><td><p>2.7</p></td></tr><tr><td><p>Dyspepsia</p></td><td><p>0.1</p></td><td><p>0.6</p></td><td><p>1.4</p></td></tr><tr><td><p>Rash</p></td><td><p>0.1</p></td><td><p>0.6</p></td><td><p>1.4</p></td></tr><tr><td><p>At least one of the above</p></td><td><p>34</p></td><td><p>29</p></td><td><p>20</p></td></tr></tbody></table><p>*T = tinidazole, used in place of metronidazole in one clinical study</p><p>P = pantoprazole; C = clarithromycin; A = amoxycillin; M = metronidazole</p><p>&nbsp;</p><p><strong>Pantoprazole Table 2</strong></p><p>Adverse Events (&ge; 1%) Reported in Clinical Trial Comparing Quadruple and Triple Therapies for <em>H pylori</em>&nbsp;Eradication Regardless of Causality</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Adverse</strong><strong> event</strong></p></td><td><p><strong>PBMT</strong><strong> </strong></p><p><strong>(n</strong><strong> = 422)</strong></p></td><td><p><strong>BMT</strong><strong> </strong></p><p><strong>(n</strong><strong> = 600)</strong></p></td><td><p><strong>PAC</strong><strong> </strong></p><p><strong>(n</strong><strong> = 368)</strong></p></td></tr><tr><td><p><strong>Skin &amp; appendages disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rash</p></td><td><p>7 (1.7%)</p></td><td><p>16 (2.7%)</p></td><td><p>4 (1.1%)</p></td></tr><tr><td><p>Pruritus ani</p></td><td><p>-</p></td><td><p>7 (1.2%)</p></td><td><p>-</p></td></tr><tr><td><p><strong>Central &amp; peripheral nervous</strong><strong> </strong><strong>system</strong><strong> disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Headache</p></td><td><p>49 (11.6%)</p></td><td><p>65 (10.8%)</p></td><td><p>38 (10.3%)</p></td></tr><tr><td><p>Dizziness</p></td><td><p>30 (7.1%)</p></td><td><p>38 (6.3%)</p></td><td><p>25 (6.8%)</p></td></tr><tr><td><p><strong>Special senses other, disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Taste perversion</p></td><td><p>45 (10.7%)</p></td><td><p>65 (10.8%)</p></td><td><p>67 (18.2%)</p></td></tr><tr><td><p><strong>Psychiatric</strong><strong> disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Anorexia</p></td><td><p>11 (2.6%)</p></td><td><p>19 (3.2%)</p></td><td><p>17 (4.6%)</p></td></tr><tr><td><p>Somnolence</p></td><td><p>-</p></td><td><p>8 (1.3%)</p></td><td><p>-</p></td></tr><tr><td><p>Depression</p></td><td><p>-</p></td><td><p>-</p></td><td><p>4 (1.1%)</p></td></tr><tr><td><p><strong>Gastrointestinal</strong><strong> disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Diarrhoea</p></td><td><p>49 (11.6%)</p></td><td><p>56 (9.3%)</p></td><td><p>37 (10.1%)</p></td></tr><tr><td><p>Nausea</p></td><td><p>38 (9.0%)</p></td><td><p>58 (9.7%)</p></td><td><p>34 (9.2%)</p></td></tr><tr><td><p>Abdominal pain</p></td><td><p>27 (6.4%)</p></td><td><p>37 (6.2%)</p></td><td><p>24 (6.5%)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Adverse</strong><strong> event</strong></p></td><td><p><strong>PBMT</strong><strong> </strong></p><p><strong>(n</strong><strong> = 422)</strong></p></td><td><p><strong>BMT</strong><strong> </strong></p><p><strong>(n</strong><strong> = 600)</strong></p></td><td><p><strong>PAC</strong><strong> </strong></p><p><strong>(n</strong><strong> = 368)</strong></p></td></tr><tr><td><p>Vomiting</p></td><td><p>7 (1.7%)</p></td><td><p>12 (2.0%)</p></td><td><p>8 (2.2%)</p></td></tr><tr><td><p>Faeces discoloured</p></td><td><p>7 (1.7%)</p></td><td><p>18 (3.0%)</p></td><td><p>-</p></td></tr><tr><td><p>Tongue discolouration</p></td><td><p>10 (2.4%)</p></td><td><p>11 (1.8%)</p></td><td><p>-</p></td></tr><tr><td><p>Mouth dry</p></td><td><p>-</p></td><td><p>13 (2.2%)</p></td><td><p>4 (1.1%)</p></td></tr><tr><td><p>Constipation</p></td><td><p>-</p></td><td><p>-</p></td><td><p>8 (2.2%)</p></td></tr><tr><td><p>Dyspepsia</p></td><td><p>-</p></td><td><p>6 (1.0%)</p></td><td><p>-</p></td></tr><tr><td><p><strong>Respiratory system disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Pharyngitis</p></td><td><p>8 (1.9%)</p></td><td><p>9 (1.5%)</p></td><td><p>7 (1.9%)</p></td></tr><tr><td><p><strong>Body</strong><strong> </strong><strong>as<strong> </strong>a whole &ndash; general&nbsp;disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Influenza-like symptoms</p></td><td><p>15 (3.6%)</p></td><td><p>12 (2.0%)</p></td><td><p>14 (3.8%)</p></td></tr><tr><td><p>Chest pain</p></td><td><p>5 (1.2%)</p></td><td><p>-</p></td><td><p>4 (1.1%)</p></td></tr><tr><td><p><strong>Resistance mechanism&nbsp;disorders</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Moniliasis</p></td><td><p>6 (1.4%)</p></td><td><p>-</p></td><td><p>5 (1.4%)</p></td></tr></tbody></table><p>---- Events reported by &lt; 1%</p><p>&nbsp;</p><p>-&nbsp; To report any side effect(s):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Saudi Arabia:</em></strong></p><p><strong>The</strong><strong> </strong><strong>National</strong><strong> </strong><strong>Pharmacovigilance</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Drug Safety Centre (NPC)</strong></p><p>Fax: +966‐11‐205‐7662</p><p>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</p><p>Toll free phone: 8002490000</p><p>E‐mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms</strong></p><p>There are no known symptoms of overdosage in humans. In individual cases 240 mg has been administered IV or orally and was well tolerated. As pantoprazole is extensively protein bound, it is not readily dialyzable. As in any case of overdosage, treatment should be symptomatic and supportive measures should be utilised.</p><p>&nbsp;</p><p><strong>Treatment</strong></p><p>Standard detoxification procedures apply.</p><p>&nbsp;</p><p><strong>Contact the Poison Information Centre on your region for advice on the management of over dosage.</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole inhibits specifically and dose proportionately H+/K+-ATPase, the enzyme which is responsible for gastric acid secretion in the parietal cells of the stomach. The substance is a substituted benzimidazole which accumulates in the acidic environment of the parietal cells after absorption. There, it is converted into the active form, a cyclic sulfenamide which binds to the H +/K+-ATPase, thus inhibiting the proton pump and causing potent and long lasting suppression of basal and stimulated gastric acid secretion. As pantoprazole acts distal to the receptor level it can influence gastric acid secretion irrespective of the nature of the stimulus (acetylcholine, histamine, gastrin). Pantoprazole&#39;s selectivity is due to the fact that it only exerts its full effect in a strongly acidic environment (pH &lt; 3), remaining mostly inactive at higher pH values. As a result, its complete pharmacological, and thus therapeutic, effect can only be achieved in the acid secretory parietal cells. By means of a feedback mechanism this effect is diminished at the same rate as acid secretion is inhibited.</p><p>&nbsp;</p><p>As with other proton pump inhibitors and H2-receptor inhibitors, treatment with pantoprazole causes a reduced acidity in the stomach and thereby an increase in gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible.</p><p>&nbsp;</p><p>Helicobacter pylori is associated with duodenal and gastric ulcer disease in about 95 and 70% of patients, respectively. H. pylori is the major factor in the development of gastritis and ulcers in such patients. Recent evidence also suggests a causative link between H. pylori and gastric carcinoma. An attempt to eradicate H. pylori is recommended in most patients with duodenal and gastric ulcer where the latter is not caused by nonsteroidal anti-inflammatory drug (NSAID) ingestion (see DOSAGE AND ADMINISTRATION). In an experimental study in mice, pantoprazole at a dose of 100 mg/kg three times daily increased the inhibitory potency of amoxycillin, clarithromycin and tetracycline against Helicobacter felis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole is rapidly absorbed and the maximal plasma concentration appears after one single oral dose. After single and multiple oral doses, the median time to reach maximum serum concentrations was approximately 2.5 hours, with a Cmax of approximately 1.2 microgram/mL. Terminal half-life is approximately one hour. Volume of distribution is approximately 0.15 L/kg and clearance is approximately 0.1 L/hour/kg. Pharmacokinetics do not vary after single or repeated administration. The plasma kinetics of pantoprazole are linear (in the dose range of 10 to 80 mg) after both oral and intravenous (IV) administration. Pantoprazole is completely absorbed after oral administration. The absolute bioavailability of the tablet is approximately 77%. Concomitant intake of food had no influence on area under the curve (AUC), maximum serum concentrations and thus bioavailability.</p><p>The serum protein binding of pantoprazole is approximately 98%. Pantoprazole is rapidly eliminated from serum and is almost exclusively metabolised in the liver. Renal elimination represents the most important route of excretion (approximately 80%) for the metabolites of pantoprazole; the rest are excreted with the faeces. The main metabolite in both the serum and urine is desmethyl-pantoprazole which is conjugated with the sulfate. The half-life of the main metabolites (approximately 1.5 hours) is not much longer than that of pantoprazole.</p><p>Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Pantoprazole metabolism is independent of the route of administration (intravenous or oral). The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity. CYP2C 19 displays a known genetic polymorphism due to its deficiency in some sub- populations (e.g. 3% of Caucasians and African-Americans and 17-23% of Asians). Although these sub- populations of slow pantoprazole metabolizers have elimination half-life values of 3.5 to 10.0 hours, they still have minimal accumulation (8 23%) with once daily dosing.</p><p>In patients with liver cirrhosis given a single 40 mg tablet, the half-life increases to between seven and nine hours and the AUC values are increased by a factor of six to eight but the maximum serum concentration increases only slightly by a factor of 1.5 in comparison with healthy subjects. After a single 20 mg tablet, AUC increased threefold in patients with mild hepatic impairment and fivefold in patients with severe hepatic impairment compared with healthy controls. Mean elimination half-life was 3.3 hours in mild hepatic impairment and six hours in severe hepatic impairment compared with 1.1 hours in controls. The maximum serum concentration only increased slightly by a factor of 1.3 compared with healthy subjects.</p><p>In patients &nbsp;with renal&nbsp; impairment (including&nbsp; those undergoing dialysis) no dose reduction&nbsp; is required.</p><p>Although the main metabolite is moderately increased, there is no accumulation. The half-life of pantoprazole is as short as in healthy subjects. Pantoprazole is poorly dialysable.</p><p>The slight increase in AUC and Cmax in elderly volunteers compared with their younger counterparts is also not clinically relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Available</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Name </strong><strong>of the excipients(s)</strong></p></td></tr><tr><td><p>Lactose</p></td></tr><tr><td><p>Mannitol</p></td></tr><tr><td><p>Crospovidone</p></td></tr><tr><td><p>Microcrystalline Cellulose</p></td></tr><tr><td><p>Magnesium Stearate</p></td></tr><tr><td><p>Hypromellose</p></td></tr><tr><td><p>Polyethylene Glycol 8000</p></td></tr><tr><td><p>Anhydrous Sodium Carbonate</p></td></tr><tr><td><p>Methacrylic Acid Copolymer Type C</p></td></tr><tr><td><p>Triethyl Citrate</p></td></tr><tr><td><p>Talc Titanium Dioxide</p></td></tr><tr><td><p>Iron Oxide Yellow</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. Protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Primary packaging:</strong> Blister (Alu/Alu)</p><p><strong>Secondary packaging:</strong> Carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If your doctor or pharmacist tells you to stop taking this medicine or it has passed its expiry date, your pharmacist can dispose of the remaining medicine safely.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., 150 Signet Toronto, Ontario, M9L 1T9 Canada.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>